Navigation Links
DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments
Date:5/15/2009

PRINCETON, N.J., May 15 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, today announced its financial results for the first quarter of 2009.

DOR's revenues for the first quarter of 2009 were approximately $0.5 million compared to $0.7 million for the first quarter of 2008. The decreased revenues were primarily attributable to decreased research and development amounts drawn down from DOR's NIH Biodefense grants.

DOR's net loss for the first quarter of 2009 was approximately $2.1 million, or $0.01 per share, compared to $1.4 million, or $0.01 per share, for the first quarter of 2008. This increase was primarily attributed to increased spending of $968,996 in research and development in preparation for the initiation of the confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

Research and development expenses for the first quarter of 2009 were approximately $1.6 million, compared to $0.6 million for the first quarter of 2008. General and administrative expenses for the first quarter of 2009 were approximately $0.5 million, compared to $0.8 million for the first quarter of 2008.

"We are pleased with our progress thus far in 2009," stated Christopher J. Schaber, PhD, President and CEO of DOR. "We continue to work diligently towards the initiation of our confirmatory Phase 3 clinical trial of orBec(R) in GI GVHD under a Special Protocol Assessment (SPA) with the FDA. We are also pleased with our new partnership with Sigma-Tau Pharmaceuticals. We now have an experienced partner in the HSC transplant arena, regulatory clarity with regard to the Phase 3 development of orBec(R), and a relatively clean capital structure. These new factors give us confidence that 2009 will be a year of substantial growth and progress for DOR."


'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LA JOLLA, Calif. , April 21, 2015 ... (JCVI), a not-for-profit genomic research organization, published a ... manipulate a type of microalgae called diatoms. The ... , Ph.D. and senior author Philip Weyman ... methods will enable better understanding of diatom genetics ...
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... a multi-arm Phase 1 study of MM-141, a bispecific ... in an oral session by Dr. Mansoor Saleh ... Research Annual Meeting in Philadelphia, PA. ... MM-141 as a monotherapy and in combination with everolimus ...
(Date:4/21/2015)... ENGLEWOOD, Colo. , April 21, 2015 ... details for a scheduled investor call on Thursday, April ... in using the instructions as follows: ... toll-free number: (844) 789-4877 International toll number: (925) ... emailed in advance to Tina Amirkiai , ...
(Date:4/21/2015)... FOREST, Calif. , April 21, 2015 ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... today announced that Dr. Mark W. ... at the 3rd Annual BioLogistics Summit in ...
Breaking Biology Technology:Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... Inc. (Amex: IMA ), a leading manufacturer ... and professional markets, announced,today that it will attend ... Conference being held May 28, 2008 at the ... Management, and Jon Russell, Vice,President, Finance, will attend. ...
... , - Production Increase Brings Large Disease ... AMT), a leader in the field,of human gene ... and Development Agreement from the National Heart, Lung, ... Health (NIH), Bethesda,Maryland, that promises to substantially enhance ...
... Screening and Treatment, and an Apparent Higher Prevalence ... Than in North America and Australia, BARCELONA, Spain, May ... women surveyed from Europe, North America, and,Australia reported having one ... women considered to be at high risk for a fracture, ...
Cached Biology Technology:Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008 2AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 2AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 3Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 2Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 3Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 4
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... threatened? Hungry? Looking for a mate? Move! Tracking and remote ... find out what they are up to. However, general theories ... Ecology in the journal Proceedings of the National Academy ... organisms as diverse as gut bacteria, tree seeds, ants, marine ...
... in French . Plant researchers ... have announced a major breakthrough in a developmental process ... the reversal of what is called epigenetic silencing in ... a better understanding of gene regulation in the continuing ...
... sedentary lifestyles and filter-feeding habits, clams have been silent ... their waters. These clams are silent no more, ... Sea Lab and her colleagues have reported in their ... . Using stable isotope techniques, Carmichael demonstrated it ...
Cached Biology News:New movement models tested at the Smithsonian in Panama 2Plants display 'molecular amnesia' 2Plants display 'molecular amnesia' 3
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Complete cell culture media with cytokines...
...
Biology Products: